#Health / Well-being #Diagnostics
- Alzheimer
- Silent phase
- Diagnostics
- Preventative treatment
- Animal model
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Health / Well-being #Diagnostics
AgenT is developing an unprecedented blood test to identify patients with Alzheimer’s disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer’s disease.
BACKGROUND
The development of AgenT’s exclusive and patented animal model began in 2012. Its inventor, Jérôme Braudeau, PhD in neurosciences, joined forces thereafter with Baptiste Billoir in 2016 to create AgenT in 2018.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
The only way to find an effective treatment for Alzheimer’s disease is to concentrate on its silent phase (15 to 20 years before its diagnosis as currently practiced).
That is why AgenT is developing an unprecedented silent-phase blood test and treatments to prevent the development of symptoms
ACCOMPLISHMENTS / COLLABORATIONS / HIGHLIGHTS
AgenT’s animal model, the foundation of its activities, has been described in mice (Audrain et al, 2016) and rats (Audrain et al, 2017). The scientific aspects of the company’s vision were also validated in a 2018 publication (Souchet et al, 2018).
COLLABORATIONS SOUGHT
AgenT is actively searching for financial (campaign underway), academic and private partners to advance in the fight against Alzheimer’s disease.
1 patent (+ 1 exclusive use license)
STRENGHTS
The only company working on the silent phase of Alzheimer’s disease and developing a diagnostic test and preventative treatments for deployment in that phase.
AgenT has the only animal model accurately reproducing the clinical progression of Alzheimer’s disease, particularly in the silent phase.
AgenT’s founders have renowned expertise in Alzheimer’s disease
INNOVATION ASSETS
A unique, disruptive animal model.
In the same field